AUTHOR=Yang Xue-Gang , Sun Yan-Yuan , Li De-Shan , Xu Guo-Hui , Huang Xiao-Qi 

TITLE=Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.940009

DOI=10.3389/fimmu.2022.940009

ISSN=1664-3224

ABSTRACT=<sec><title>Purpose</title><p>To assess the effectiveness and safety of drug-eluting beads transarterial chemoembolization plus immune checkpoint inhibitors (DEB-TACE+ICIs) versus chemotherapy (gemcitabine+cisplatin) for patients with unresectable intrahepatic cholangiocarcinoma (iCCA).</p></sec><sec><title>Materials and Methods</title><p>This retrospective study included unresectable iCCA patients treated with DEB-TACE+ICIs or chemotherapy between May, 2019 and August, 2021. The differences in tumor responses, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) were compared between the 2 groups. Patient baseline characteristics, PFS, and OS were compared among 2 groups before and after propensity score-matching (PSM). Factors affecting PFS and OS were analyzed by Cox’s proportional hazards regression model.</p></sec><sec><title>Results</title><p>The study included 49 patients with unresectable iCCA patients, 20 in the DEB-TACE+ICIs group and 29 in the chemotherapy group. PSM analysis created 20 pairs of patients in 2 groups. The patients in the DEB-TACE+ICIs group had a higher objective response rate (55.0% vs. 20.0%, <italic>P</italic>=0.022), higher PFS (median, 7.2 vs. 5.7 months, <italic>P</italic>=0.036), and higher OS (median, 13.2 vs. 7.6 months, <italic>P</italic>=0.015) than those in the chemotherapy group. Multivariate analyses suggested that chemotherapy, tumor size &gt;5cm, and multiple tumors were the independent risk factors for PFS and OS. The incidence of TRAEs was similar between the 2 groups.</p></sec><sec><title>Conclusion</title><p>Compared to chemotherapy, DEB-TACE plus ICIs improved survival and was well-tolerated in patients with unresectable iCCA.</p></sec>